Gout

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

Response rates in the DISSOLVE I and DISSOLVE II high-dose and low-dose groups receiving SEL-212 were significantly different from the placebo group.

An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.

An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

An analysis of NHANES data from 2011-2018 presented at EULAR 2023 offers an overview of the disproportionate growth in gout burden for Asian Americans relative to their White counterparts.

The findings suggest rural patients treated for gout had higher treatment adherence compared with urban patients.

Chronic tophaceous gout was demonstrated to be an independent risk factor linked to the development of colorectal cancer.

A Cox regression analysis showed a significant association between a gout diagnosis and subsequent breast cancer diagnosis in the total population.

Our latest case report from Brady Pregerson, MD, featuresa woman in her mid-60s with a history of Hashimoto’s thyroiditis treated with levothyroxine presenting to the hospital with 4-5 days of pain, swelling and redness on her left thumb.

Between 2011 and 2018, age- and sex-adjusted prevalence among Asian Americans doubled from 3.3% to 6.6%, which exceeded all other ethnic and racial groups.

A negative relationship between bone mineral density (BMD) and hyperuricemia in total, as well as in the L1, L2, and L3 lumbar vertebrae, was demonstrated in the multivariable-adjusted regression models.

Patients with intercritical gout had higher CXCL12 levels, IL-18, and IL-1β when compared with controls.

Although women with gout reported more severe symptoms and significantly worse illness perception and quality of life, they were given less information on ways to self-manage their condition.

No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.

Patients with cirrhosis had higher mortality rates, tophi, and gout flare.

An analysis of eGFR changes based on methotrexate use in the MIRROR trial offers new insight into the effects of pegloticase on renal function.

The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.

The meta-analysis observed an enhanced plasma uric acid concentration in patients with periodontitis when compared with controls.

SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.

An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.

Dialysis-dependent patients in the US with gout have an increased risk of cardiovascular comorbidities, hospitalization, and mortality. Results emphasize the need for improved treatments to enhance outcomes for this patient population.

An international pilot study shows a probiotic candidate may improve both management of gout and relevant blood serum levels in treated patients.

A brief increase in venous thromboembolism (VTE) was reported within 30 days after a hospitalization or primary care visit for gout flare. The highest incidence occurred during the 16-30 day period after the flare.

Investigators evaluated the link between gout and thalassemia using data from Taiwan's Longitudinal Health Insurance Database 2000 (LHID 2000).

Of the 23 biomarkers identified in patients with gouty arthritis and hyperuricemia, kynurenic acid, thymine, and phosphatidylinositol (PI) differed from previous gout research.

Patients' perceptions of the effectiveness and necessity of allopurinol for gout treatment proved to be strong factors influencing intentional adherence.

Ginger Hultin, MS, RDN, explained the benefits of an anti-inflammatory nutrition plan for patients living with rheumatic and autoimmune conditions, as well as what rheumatologists need to know.

An analysis of the DELIVER and DAPA-HF trials provides an overview of the impact of gout on heart failure outcomes and effects of dapagliflozin in this patient population.